Crystalline forms of therapeutic compounds and uses thereof

• US 10,253,036 B2
• Filed: 09/01/2017
• Issued: 04/09/2019
• Est. Priority Date: 09/08/2016
• Status: Active Grant

• Current Assignee: Kala Bio, Inc.
• Original Assignee: Kala Pharmaceuticals, Inc.
• Inventors: Nguyen, Minh Ngoc, Ong, Winston Zapanta
• Primary Examiner(s): McDowell, Brian E
• Application Number:
  US15/694,331
• Publication Number:
  US 20180065978A1
• Time in Patent Office: 585 Days
• CPC Class Codes: A61K 31/517 ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
• CPC Class Codes: C07B 2200/13 Crystalline forms, e.g. polymorphs
• CPC Class Codes: C07D 491/107 with only one oxygen atom as ring hetero atom in the oxygen-containing ring

Abstract

Described herein are crystalline forms of Compound 1 useful for the prevention and treatment of angiogenic ocular conditions; methods of treating a disease comprising; processes for preparing; and kits comprising, the same.

Claims

1. A crystalline form of Compound 1:

2. The compound of claim 1, wherein the crystalline form is a hydrate.

3. A process for preparing a crystalline form of claim 1, comprising:

crystallizing amorphous Compound 1 from 1;

9 of water;

isopropanol; and

recovering the crystallized material from the solvent.

4. A pharmaceutical composition comprising the crystalline form of claim 1 and a pharmaceutically acceptable carrier.

5. The pharmaceutical composition of claim 4, wherein the pharmaceutical composition is suitable for topical administration.

6. The pharmaceutical composition of claim 4, wherein the pharmaceutical composition is suitable for injection.

7. The pharmaceutical composition of claim 4, wherein the pharmaceutical composition is suitable for delivery to the eye.